A Phase 1/2, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218
Phase of Trial: Phase I/II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs ALN-HBV02 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Vir Biotechnology
- 19 Nov 2019 According to a Vir Biotechnology media release, the company has completed dosing of all patient cohorts receiving 50-200 mg. The company anticipate additional data for this trial to be available in the first half of 2020.
- 06 Dec 2018 According to an Alnylam Pharmaceuticals media release, data read out from this trial is expected in 2019.
- 26 Nov 2018 Status changed from not yet recruiting to recruiting.